Clinical Trial

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults

Name: A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults — clinical trial record (NCT07616934)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, and immunogenicity of VAX-A1 in healthy adults 18-40 years of age.

Protocol Amendment History 1 change

critical Recruitment opened 2026-06-17

Trial Details

NCT Number	NCT07616934
Lead Sponsor	Vaxcyte, Inc.
Conditions	Group A Streptococcal Infection
Enrollment	80 participants
Start Date	2026-06-01
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-16